{
  "docId": "019de076-2351-76a2-9dc5-1c75bf1dd158",
  "docSlug": "905d9ceaf5cb608feb86b583a8401e54",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 45 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 45,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "Includes a navigation bar at the top indicating this is part of a larger presentation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-2351-76a2-9dc5-1c75bf1dd158/20",
  "deckHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158",
  "deckJsonHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158.json",
  "deckAnchorHref": "/decks/019de076-2351-76a2-9dc5-1c75bf1dd158#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.28,
        "x": 0.68,
        "y": 0.32
      },
      "kind": "chart",
      "text": "Advancing T-cell receptor therapies acquired from Neogene",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d0a461b-1a98-48dd-b8f0-d52fadcce776",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.3,
        "x": 0.15,
        "y": 0.45
      },
      "kind": "chart",
      "text": "CAR copies in peripheral blood",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "61fabe6c-692d-4476-92cc-39b7b31cf567",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.03,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Designed by AstraZeneca and manufactured and developed in China by Cellular Biomedicine group. CAR(-T) = chimeric antigen receptor(-T cell); TGFβRIIDN = dominant negative transforming growth factor β receptor II; GPC3 = Glypican 3; FIH = first-in-human; HCC = hepatocellular carcinoma; STEAP2 = human 6-transmembrane epithelial antigen of prostate 2; IND = investigational new drug. Acquisition of Neogene Therapeutics was completed on 16 January 2023, Neogene Therapeutics is a global clinical-stage biotechnology company focused on discovery, development and manufacturing of next-generation T cell receptor therapies.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04c0efb2-304c-485c-b0e2-a47a1f039b67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.15,
        "x": 0.69,
        "y": 0.65
      },
      "kind": "image",
      "text": "Cellectis",
      "attrs": null,
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79447a27-156a-4dc9-91b4-522ebb4ca7e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.18,
        "x": 0.48,
        "y": 0.45
      },
      "kind": "list",
      "text": "Encouraging FIH data in HCC; Strong expansion and persistence of CAR-T cellular kinetics; Promising anti-tumour activity, objective responses in several patients",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6367ea87-4da9-44dd-91a0-c86b128cb3d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.8,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "In-house development and strategic collaborations expand our reach in cell therapy",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "71411d64-4fc5-472a-ac09-d991bacbc723",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.4,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology – R&D highlights",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aab7d910-e3a4-48dc-acaa-85409f483bd5",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "0678d219-17dd-4fe0-a27b-774a6d58a527",
      "evidence": "The use of a bar chart and a line chart effectively communicates data.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 15,
      "beatId": "88166dd9-a0d1-4ffb-ac51-e141aedff5d2",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Key takeaways and highlights from Oncology and BioPharmaceuticals",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 5,
      "name": "Logic Chain",
      "slug": "01-logic-chain",
      "bestFor": "Skeptical audiences, controversial recommendations, rigorous analysis",
      "matchId": "4272c71f-edd6-48f7-a353-789a42575177",
      "evidence": "The document walks through a logical chain of financial performance, portfolio evolution, and R&D highlights",
      "position": 0,
      "objective": "How AstraZeneca's diversified portfolio drives growth",
      "structure": "Premise 1 (Accepted truth) -> Premise 2 (Observed fact) -> Therefore... (Inevitable conclusion)",
      "confidence": 0.7,
      "description": "Build an airtight chain of logic where each premise leads inevitably to the conclusion"
    },
    {
      "to": 20,
      "from": 13,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "f01e337f-a074-4bb0-a0a6-8afab8af6ed6",
      "evidence": "The document highlights the potential consequences of inaction in not leveraging technology for better patient outcomes",
      "position": 1,
      "objective": "The importance of harnessing technology to deliver better patient outcomes",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}